OverviewSuggest Edit

Arrowhead Pharmaceuticals is focused on developing innovative drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein.

TypePublic
Founded2004
HQPasadena, CA, US
Websitearrowheadpharma.com
Employee Ratings4

Latest Updates

Employees (est.) (Sept 2019)134(+16%)
Job Openings39
Revenue (FY, 2019)$168.8 M(+946%)
Share Price (Oct 2021)$66(-1%)
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Arrowhead Pharmaceuticals

Christopher Anzalone

Christopher Anzalone

President and Chief Executive Officer, Director
James Hamilton

James Hamilton

Senior Vice President, Discovery and Translational Medicine
Patrick O'Brien

Patrick O'Brien

General Counsel, Corporate Secretary, and Chief Compliance Officer
Ken Myszkowski

Ken Myszkowski

Chief Financial Officer
Thomas Schluep

Thomas Schluep

Vice President, Program Management
Dave Bormett

Dave Bormett

Vice President, Quality Assurance
Show more

Arrowhead Pharmaceuticals Office Locations

Arrowhead Pharmaceuticals has offices in Pasadena, Madison and San Diego
Pasadena, CA, US (HQ)
177 E Colorado Blvd #700
Madison, WI, US
502 S Rosa Rd
San Diego, CA, US
11404 Sorrento Valley Rd
Show all (3)

Arrowhead Pharmaceuticals Financials and Metrics

Arrowhead Pharmaceuticals Revenue

Arrowhead Pharmaceuticals's revenue was reported to be $168.8 m in FY, 2019
USD

Revenue (Q3, 2021)

45.9m

Net income (Q3, 2021)

(29.9m)

EBIT (Q3, 2021)

(31.9m)

Market capitalization (22-Oct-2021)

6.9b

Closing stock price (22-Oct-2021)

66.0

Cash (30-Jun-2021)

326.0m

EV

6.6b
Arrowhead Pharmaceuticals's current market capitalization is $6.9 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

382.0k158.3k31.4m16.1m168.8m

Revenue growth, %

118%(59%)19736%(49%)

General and administrative expense

7.9m9.9m6.8m19.1m26.6m

R&D expense

47.3m41.5m31.7m53.0m81.0m
Quarterly
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

81.2m85.4m24.8m30.1m221.8m

Accounts Receivable

67.8k327.4k661.4k

Prepaid Expenses

3.3m

Inventories

2.8m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

62.2m50.3m43.6m102.1m61.7m38.4m11.5m69.8m28.0m189.8m161.6m188.3m461.0m256.7m219.3m139.9m372.4m326.0m

Accounts Receivable

580.8k937.3k149.9k16.3k15.0k3.2m13.4m2.0m1.3m1.3m21.7m9.0m955.0k671.0k

Prepaid Expenses

3.1m2.7m3.1m4.1m7.1m6.6m7.3m

Current Assets

82.3m66.1m49.6m106.2m89.7m77.9m53.1m92.7m61.9m249.0m235.0m244.5m507.6m314.5m315.2m323.7m586.8m526.0m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(91.9m)(81.7m)(34.4m)(54.5m)68.0m

Depreciation and Amortization

2.3m3.3m4.7m4.7m4.4m

Inventories

2.8m

Accounts Payable

2.5m2.6m(3.5m)(1.3m)4.8m
USDFY, 2015

Revenue/Employee

3.7k

Financial Leverage

1.2 x
Show all financial metrics

Arrowhead Pharmaceuticals Operating Metrics

FY, 2016

Facilities

2

Patent Applications

256

Patents Issued

359

Pre-Clinical Phase Products

6
Show all operating metrics

Arrowhead Pharmaceuticals Online and Social Media Presence

Embed Graph

Arrowhead Pharmaceuticals News and Updates

Thinking about trading options or stock in Arrowhead Pharmaceuticals, United Parcel Service, MGM Resorts, Moderna, or Microsoft?

NEW YORK, Sept. 16, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARWR, UPS, MGM, MRNA, and MSFT. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Arrowhead Pharmaceuticals Blogs

Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases

- KOL Webinar Tomorrow, October 26, 2021 at 3:00 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Oct. 25, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to begin a Phase 1/2a clinical trial of ARO-C3, the company’s investigational RNA

Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases

Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases Content Import Tue, 10/12/2021 - 16:01 Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases Oc…

Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia

Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia Content Import Thu, 09/30/2021 - 07:31 Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia Sep 30, 2021 at 7:30 AM EDT …

Arrowhead Pharmaceuticals to Participate in Upcoming October 2021 Conferences

PASADENA, Calif. --(BUSINESS WIRE)--Sep. 29, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Chardan's 5th Annual Genetic Medicines Conference – October 4-5, 2021 October 4, 2021 , 4:30 p.m.

Arrowhead Earns $10 Million Phase 1 Milestone Payment

PASADENA, Calif. --(BUSINESS WIRE)--Sep. 28, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it earned a $10 million milestone payment from Janssen Pharmaceuticals, Inc. , (Janssen) part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences

Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences Content Import Wed, 09/01/2021 - 07:31 Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences Sep 1, 2021 at 7:30 AM EDT This release is a backfill from a …
Show more

Arrowhead Pharmaceuticals Frequently Asked Questions

  • When was Arrowhead Pharmaceuticals founded?

    Arrowhead Pharmaceuticals was founded in 2004.

  • Who are Arrowhead Pharmaceuticals key executives?

    Arrowhead Pharmaceuticals's key executives are Christopher Anzalone, James Hamilton and Patrick O'Brien.

  • How many employees does Arrowhead Pharmaceuticals have?

    Arrowhead Pharmaceuticals has 134 employees.

  • What is Arrowhead Pharmaceuticals revenue?

    Latest Arrowhead Pharmaceuticals annual revenue is $168.8 m.

  • What is Arrowhead Pharmaceuticals revenue per employee?

    Latest Arrowhead Pharmaceuticals revenue per employee is $1.3 m.

  • Who are Arrowhead Pharmaceuticals competitors?

    Competitors of Arrowhead Pharmaceuticals include Ionis Pharmaceuticals, X-Chem and Mycenax Biotech.

  • Where is Arrowhead Pharmaceuticals headquarters?

    Arrowhead Pharmaceuticals headquarters is located at 177 E Colorado Blvd #700, Pasadena.

  • Where are Arrowhead Pharmaceuticals offices?

    Arrowhead Pharmaceuticals has offices in Pasadena, Madison and San Diego.

  • How many offices does Arrowhead Pharmaceuticals have?

    Arrowhead Pharmaceuticals has 3 offices.